The management of left main coronary artery (LMCA) disease has evolved over the past two decades. Historically, coronary artery bypass grafting (CABG) surgery has been the gold standard for the treatment of LMCA disease. However, with the advancements in percutaneous coronary interventions (PCIs) and stent technology, PCI in select patients has achieved comparable outcomes to CABG. As such, this has led to changes in the American College of Cardiology and European Society of Cardiology guidelines, which recommend that PCI might be an alternative to CABG in select patients. In this review article, we describe the historical perspective and early experience with coronary interventions of LMCA disease, landmark clinical trials and their effect on guidelines, and the role of intravascular imaging in the management of LMCA lesions.
Historical Perspective and Early Experience
Historically, coronary artery bypass grafting (CABG) surgery has been the gold standard treatment for left main coronary artery (LMCA) disease. However, with the developments and advancements in the interventional cardiology field, percutaneous coronary intervention (PCI) has become a safe alternative management option to CABG in select patients. Today, LMCA disease is identified in about 5% of patients undergoing primary coronary intervention for evaluation of ischaemia. 1 The first left main PCI was performed by Andreas Gruntzig in 1978 using plain old balloon angioplasty (POBA). In his initial experience, Gruntzig performed POBA in 50 patients over a period of 18 months;
POBA was deemed successful in 32 patients. Using POBA, mean left main stenosis improved from 84% to 34% (p<0.001) with coronary pressure gradient improving from a mean of 58 mmHg to 19 mmHg (p<0.001). 2 POBA alone was associated with acute and subacute vessel closure, elastic recoil, late vascular remodelling and re-narrowing of coronary arteries. This led to the development of coronary stents and their progressive refinement from bare-metal stents (BMS) to drugeluting stents (DES). These newer stents addressed the shortcomings of BMS, specifically in-stent restenosis. Furthermore, the development of novel anti-platelet medications has led to significant reductions in the incidence of major adverse cardiac events (MACE).
Important Randomised Clinical Trials

Early Evidence
In a 2011 study, Boudriot et al. compared PCI using sirolimus-eluting stents with CABG for the management of LMCA disease. 3 Overall 201 patients were randomised to receive PCI (n=100) or CABG (n=101), with follow-up for 12 months. Mortality and MI rates were comparable, but PCI was associated with higher rates of repeat revascularisation and CABG was associated with higher rates of stroke. The combined primary endpoint was noninferiority in freedom from major adverse cardiac events and the need for target vessel revascularisation within 12 months; this was observed in 13.9% of patients after CABG, as opposed to 19.0% after PCI (p=0.19 for noninferiority).
Combined rates for death and MI were comparable (7.9% in the CABG group versus 5.0% in the PCI group; noninferiority p<0.001), but PCI was inferior to CABG for repeat revascularisation (5.9% versus 14.0%; noninferiority p=0.35). Perioperative complications (including two patients having strokes) were higher after CABG (4% in PCI versus 30% in CABG; p<0.001). Freedom from angina was similar between the groups (p=0.33). 3 
SYNTAX
In 2014, subgroup analysis of the Synergy Between PCI With TAXUS And Cardiac Surgery (SYNTAX) trial compared left main PCI using firstgeneration DES with CABG. 4 A total of 357 patients received PCI and 348 patients received CABG. At 5 years, in patients with SYNTAX score <33 (a scoring system that quantifies angiographic lesion complexity) the incidence of MACE was similar in the PCI and CABG groups. However, there was a higher incidence of target vessel revascularisation (TVR) in the PCI group than in the CABG group.
In patients with a high SYNTAX score (≥33), CABG had favourable outcomes compared with PCI. Major adverse cardiac and 
EXCEL and NOBLE
More recently the Evaluation of XIENCE Versus Coronary Artery Bypass
Surgery for Effectiveness of Left Main Revascularization (EXCEL) and
Nordic-Baltic-British Left Main Revascularization Study (NOBLE) trials were published. 7, 8 These two multicentre randomised clinical trials were performed to assess the outcomes of second-generation DES in left main PCIs compared with CABG.
In the EXCEL trial, a total of 1,905 patients with low-intermediate SYNTAX score of <33 were randomised to PCI versus CABG. 7 The primary endpoint was defined as a composite of all-cause death, MI and stroke at 3 years. The primary endpoint occurred in 15.4% of the patients in the PCI group and in 14.7% of the patients in the CABG group (difference of 0.7 percentage points; upper 97.5% confidence limit 4.0 percentage points; p=0.02 for noninferiority; HR 1.00; 95% CI [0.79-1.26]; p=0.98 for superiority).
The secondary endpoint was defined as a composite endpoint of all-cause death, MI or stroke at 30 days. It occurred in 4.9% of the patients in the PCI group and in 7.9% in the CABG group (p<0.001 for noninferiority, p=0.008 for superiority). The secondary endpoint event of death, stroke, MI, or ischaemia-driven revascularisation at 3 years occurred in 23.1% of the patients in the PCI group and in 19.1% in the CABG group (p=0.01 for noninferiority, p=0.10 for superiority). In summary, 30-day MACE was lower in PCI group, but similar for both the PCI and CABG at 3-year follow-up.
In the NOBLE trial, a total of 1,201 patients with low-intermediate SYNTAX score were randomised to PCI using biolimus-eluting stents versus CABG. 8 The 30-day outcomes were similar to those of the EXCEL trial, but 
MAIN-COMPARE Registry
In 2018, in the observational cohort study of the Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty versus Surgical Revascularization (MAIN-COMPARE) registry, the 10-year outcomes of PCI and CABG were assessed. 9 The overall cohort found that there was no significant difference in the adjusted risk of death and composite outcomes between both groups at 10 years. However, there was a higher rate of TVR in the PCI group.
Meta-analyses
Several meta-analyses of these major clinical trials have shown that PCI has similar rates of MACE compared to CABG over 3-5 years in the management of LMCA disease, with PCI being associated with higher repeat revascularisation rates and CABG being associated with higher stroke rates in the early follow-up period. Moreover, these Tables   1 and 2 ). 10 The incidence of MACCE at 3 to 5 years of follow-up was significantly higher with PCI compared to CABG (23.3% versus 18.2%, OR 1.37; 95% CI [1.18-1.58]; p=<0.0001; I 2 =0%) and was largely driven by more repeat revascularisation procedures among patients treated with PCI. There was no statistically significant difference in rates of mortality, MI or stroke (either individually or when these outcomes were combined as a composite endpoint). Figures 1 and 2 summarise MACCE with an analysis by SYNTAX score and generation of stent. [10] [11] [12] The CathPCI Registry remodelling and plaque burden. 15 Compared to infrared light of optical coherence tomography (OCT), intravascular ultrasound has a higher tissue penetration and does not have the limitations of OCT in imaging the left main ostium. 16 The minimal luminal area (MLA) is the most accepted variable for detecting a significant lesion, with a sensitivity of 93% and of specificity 95%, with MLA <6.0 mm 2 . Yet this was determined in predominantly western populations. MLA cut-off value can vary within different populations due to difference in body mass and vessel size. In asian patients, MLA <4.8 mm 2 and MLA <4.1 mm 2 were found to be significant for left main disease and had a sensitivity of 77%, 95% and specificity 82%, 83% respectively. [17] [18] [19] Another modality to assist in the decision making process is physiological assessment of the lesion using Fractional flow reserve (FFR) with a cut-off of <0.08 indicating an important flow-limiting stenosis. A limitation to FFR is its inability to accurately determine the significance of the stenosis in the presence of tandem lesions. However, FFR may still play a significant role in the treatment of left main coronary artery bifurcation disease.
For example, it can be useful in determining the significance of an ostial stenosis of the side branch (usually the left circumflex artery) and the need for a two-stent strategy. [20] [21] 
European and American Guidelines
The standard of care for LMCA disease for many years has been CABG over medical therapy because of mortality benefit. 22 10 Reproduced with permission from Elsevier. 10 Reproduced with permission from Elsevier. Test for overall effect: z=6.08 (p<0.00001) CABG = coronary artery bypass grafts; CVA = cerebrovascular accident; PCI = percutaneous coronary intervention. Source: Moore et al. 2017 . 10 Reproduced with permission from Elsevier. have not yet been incorporated into the guidelines.
Conclusion
In conclusion, left main PCI can be performed safely in select patients. The decision to proceed with PCI versus CABG is best made through a multidisciplinary approach consisting of a clinical cardiologist, interventional cardiologist and a cardiac surgeon. It entails consideration of the patient's preferences and expectations, comorbidities, the estimated surgical risk, the complexity of coronary anatomy and the patient's ability to comply with dual antiplatelet therapy. Appropriate evaluation of the lesion by coronary angiography and intravascular imaging coupled with operator expertise remains paramount to the decision-making process and strategy. Furthermore, all patients with LMCA disease will require optimal guideline-directed secondary prevention and lifestyle intervention in addition to the chosen revascularisation strategy. 25 Reproduced with permission from Oxford University Press on behalf of the European Society of Cardiology.
